Targeting cell death signaling in colorectal cancer: Current strategies and future perspectives

Table 2 Targeting autophagy in colorectal cancer: An overview of current clinical trials

Drug	Target	Clinical1	Ref.
Hydroxychloroquine	Autophagosome	Phase I (NCT01206530) Phase II (NCT01006369)	[122,150]
Everolimus/rapamycin	mTOR	Phase II (NCT00419159, NCT01387880)	[126,127,151]

¹Further detailed information on clinical trials: http://www.clinicaltrials.gov. The compounds shown target relevant processes or proteins involved in autophagy signaling. The phase of clinical trials is stated and trial identifier indicated in brackets where applicable. mTOR: Mammalian target of rapamycin.